NON-SMALL CELL LUNG ADENOCARCINOMA
Clinical trials for NON-SMALL CELL LUNG ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against tough cancers in early trial
Disease control Recruiting nowThis study tests a new oral drug called NXP900 in people with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The trial has two parts: first, finding the right dose, and then seeing if the drug shrinks tumors. It is a fir…
Matched conditions: NON-SMALL CELL LUNG ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests MGC028, a drug that delivers a cancer-killing agent directly to tumor cells. About 124 adults with advanced lung, bile duct, pancreatic, or colorectal cancers that have stopped responding to standard treatments will receive the drug every three weeks.…
Matched conditions: NON-SMALL CELL LUNG ADENOCARCINOMA
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC